Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TSC22 domain family member 2 (TSC22D2) is a member of the TSC22 domain family of transcription factors, which are characterized by a leucine zipper motif that mediates dimerization and DNA binding[1][2][5]. TSC22D2 reduces levels of nuclear PKM isoform M2, resulting in repression of cyclin CCND1 and reduced cell growth[5]. Its promoter may be regulated by histone H4 transcription factor (HINFP)[3]. The biological and pathological roles of this protein are not as extensively characterized as some other family members, and it is not currently considered a direct therapeutic target[4][5]. Clarifying details: The gene/protein is distinct from the better-studied TSC22 domain family member 1 (TSC22D1). As of current knowledge, TSC22D2 has limited direct therapeutic or disease relevance. There is no evidence it functions as an enzyme, receptor, transporter, or other classical drug target protein family. No small-molecule drugs or clinical interventions are known to target TSC22D2 directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TSC22 domain family member 2 (TSC22D2).